Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300

Benzinga Newsdesk www.benzinga.com Negative 89.4%

Neg 89.4% Neu 0% Pos 0%

Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.